Episode
Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs
- Podcast
- Touching Base
- Published
- Jul 25, 2025
- Duration seconds
- 2554
- Processing state
not_requested- Canonical source
- https://shows.acast.com/touching-base/episodes/sarepta-under-scrutiny-astrazenecas-big-bet-and-ai-vs-idrs
Actions
POST https://stenobird.com/v1/public/podcasts/touching-base-6714887/episodes/sarepta-under-scrutiny-astrazeneca-s-big-bet-and-ai-vs-idrs/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/touching-base-6714887/sarepta-under-scrutiny-astrazeneca-s-big-bet-and-ai-vs-idrs.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Sarepta has temporarily paused shipments of Elevidys, its FDA-approved treatment for Duchenne muscular dystrophy. In this episode of GEN 's Touching Base , we discuss the company’s response to the tragedies associated with its DMD therapy as well as with a new therapy for limb-girdle muscular dystrophy. Also in this episode, big updates from AstraZeneca including a $50 billion investment in U.S. manufacturing and R&D, a heartwarming story about preventing mitochondrial disease involving eight babies from the U.K., and from the lab of Nobel Prize winner David Baker, PhD, AI that designs drugs for previously “undruggable” proteins. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base : About Face: Sarepta to Pause Elevidys Shipments Temporarily By Alex Philippidis, GEN Edge, July 21, 2025 StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies By Alex Philippidis, GEN Edge, July 20, 2025 Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths By Alex Philippidis, GEN Edge, July 16, 2025 AstraZeneca Commits $50B More to U.S. Manufacturing, R&D Projects By Alex Philippidis, GEN Edge, July 22, 2025 AstraZeneca’s New $300M Plant Provides Control of Cell Therapy Production By Gareth John Macdonald, GEN, May 14, 2025 Beyond Baby KJ: Next Steps in Manufacturing Genome Editing Cures GEN Live, July 30, 2025 Mitochondrial Disease Milestone: Eight Babies Born Free of Disease via Pronuclear Transfer By Julianna LeMieux, PhD GEN, July 16, 2025 Undruggable No More: AI Hits Disordered Proteins, Unlocks Therapy Targets By Fay Lin, PhD GEN, July 18, 2025 H…